Back to search
Non-metastatic Castration-resistant Prostate Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Non-metastatic Castration-resistant Prostate Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Non-metastatic Castration-resistant Prostate Cancer trials you may qualify forThe purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refracto…
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Ef…
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how we…
The WOMBAT study will test if BAT can prolong the time it takes for nmCRPC prostate cancer to become detectable in other areas of the body (metastatic disease).…
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study i…
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of c…
In this observational study, participants receive darolutamide: a treatment that is already available for doctors to prescribe for non-metastatic castration-res…
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has n…